Table 1 Disease features and biopsy sites in patients with granulomatosis with polyangiitis
Variables | Results (n = 35) |
|---|---|
Age, years | 48.9 ± 12.6 |
Female, n (%) | 22 (62.9) |
Disease status | |
 Onset, n (%) | 9 (25.7) |
 Relapse, n (%) | 25 (71.4) |
 Persistent disease, n (%) | 1 (2.8) |
Years since diagnosisa | 8.7 ± 5.6 |
Disease extension | |
 Localized disease, n (%) | 29 (82.9) |
 Generalized disease, n (%) | 6 (17.1) |
Disease manifestations | |
 ENT involvement, n (%) | 34 (97.1) |
 Eye disease, n (%) | 8 (22.8) |
 Lung involvement, n (%) | 7 (20.0) |
 Glomerulonephritis, n (%) | 4 (11.4) |
 Cutaneous vasculitis, n (%) | 1 (2.8) |
ANCA positivity | |
 cANCA by IIF, n (%) | 33 (94.3) |
 PR3-ANCA by ELISA, n (%) | 32 (91.4) |
Biopsy sites | |
 Nose, n (%) | 28 (80.0) |
 Other sites, n (%) | 7 (20.0) |
Staphylococcus aureus | |
 Positive culture, n (%)b | 19 (55.9) |
Therapy | |
 No therapy, n (%) | 13 (37.1) |
 Prednisolone, n (%) | 10 (28.6) |
 Prednisolone daily dose, mg | 11.2 (9.3–20.0) |
 Daily co-trimoxazole, n (%) | 14 (40.0) |
 Cyclophosphamide, n (%) | 4 (11.4) |
 Azathioprine, n (%) | 4 (11.4) |
 Methotrexate, n (%) | 1 (2.8) |
 Mycophenolate mofetil, n (%) | 4 (11.4) |
 Cyclosporin A, n (%) | 1 (2.8) |